Brokerages Set Conatus Pharmaceuticals Inc (CNAT) Target Price at $8.87
Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have earned an average rating of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $8.87.
Several analysts recently issued reports on CNAT shares. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Tuesday, December 18th. Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 1st. SunTrust Banks reduced their price target on shares of Conatus Pharmaceuticals to $12.00 and set a “buy” rating on the stock in a research report on Thursday, December 6th. HC Wainwright reiterated a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Monday, November 5th. Finally, ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd.
A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC boosted its position in Conatus Pharmaceuticals by 94.6% in the third quarter. Virtu Financial LLC now owns 25,860 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 12,572 shares in the last quarter. Artal Group S.A. acquired a new stake in Conatus Pharmaceuticals in the third quarter valued at approximately $2,900,000. BlackRock Inc. boosted its position in Conatus Pharmaceuticals by 13.4% in the third quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock valued at $9,419,000 after buying an additional 191,287 shares in the last quarter. Jane Street Group LLC acquired a new stake in Conatus Pharmaceuticals in the second quarter valued at approximately $142,000. Finally, Paloma Partners Management Co acquired a new stake in Conatus Pharmaceuticals in the second quarter valued at approximately $547,000. Hedge funds and other institutional investors own 31.93% of the company’s stock.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%. The company had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $9.70 million. Equities research analysts predict that Conatus Pharmaceuticals will post -0.61 earnings per share for the current fiscal year.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Recommended Story: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.